UCL 1

The new UCL Future Targeted Healthcare Manufacturing Hub has been established to address manufacturing, business and regulatory challenges to ensure that new targeted biological medicines can be developed quickly and manufactured at a cost affordable to society. This national asset is valued in excess of £20M over 7 years (2017–2024).

The Hub engages leading academics across the UK as Spokes and the research will span stratified protein medicines targeted to particular patient groups through to truly personalised cell-based medicines. The Hub is unique in the biomanufacturing space, and is being supported by a large number of the leading manufacturers and suppliers in the biotherapeutics industry and non-governmental associations, including the BIA. BIA members can also engage with the hub by becoming members of the Industrial User Group.

UCL Hub Vision

  • By 2025 targeted biological medicines will transform the precision of healthcare prescription, improve patient care and quality of life.
  • The current “one-size-fits-all” approach to drug development is being challenged by the growing ability to create stratified and personalised medicines targeted to specific sub-populations and even individuals.
  • Without significant manufacturing and supply innovations, the promise of targeted healthcare will remain inaccessible for many. The impact on health and well-being is profound.
  • The Hub will be the first globally recognised consortium for the creation, delivery and dissemination of innovative manufacturing research, underpinning cost-effective, robust manufacture, supply and delivery of targeted biotherapeutics.

UCL Hub Collaboration and Deliverables

The Hub will work with its network of users and academics to deliver the vision, with the core research focusing on:

  • Grand Challenge 1: Transforming supply chain management and economics for targeted biotherapeutics with novel computational decision-support tools
  • Grand Challenge 2: Sustainable manufacturing for future targeted biotherapeutics with novel bioprocesses, analytics and control algorthims

This paradigm shift in manufacturing practice will provide the manufacturing infrastructure needed for sustainable healthcare. 

UCL2

UCL Hub Impact

The benefits of the Hub extend beyond the users who have co-developed the proposal. Our innovations will move the reality of targeted healthcare forward significantly by identifying the necessary technological and logistical solutions. Targeted interventions will provide a step change for many patients in terms of widened access to new treatments. The range of targets is huge and includes treatments for cancers and the re-programming of degenerative disorders such as dementia. This is a radical new opportunity for the industry. The Hub will undertake rapid and effective development of new clinical medicines and promises a new horizon for the sector.

For more information on the Hub, collaboration and how to join the industrial User Group please contact: Dr. Naveraj Gill, Strategic Alliance Director, Deputy Head of Department (Enterprise)

e: naveraj.gill@ucl.ac.uk  | w: www.ucl.ac.uk/biochemeng/research/hub